EpigeneticsreferstoheritablealterationsingeneexpressionthatdonotinvolvetheDNA coding sequence itself.Epigenetic regulation plays an important role in gene expression,DNA replication,rep-aration and reconstitution. Thus, the abnormity of epigenetic regulation may lead to different diseases, especially cancer.SNF5 ,which can suppress tumor significantly,is one of the core components of SWI/SNF chromosome remodeling complexes.EZH2,a histone methyltransferase,is closely and complicatedly related to cancer and has significant effect on tumorigenesis.There are many studies reporting the effects of epigenetic regulation factors-SNF5 and EZH2 on different tumors as well as the interrelation at present.In the present paper,the advances in the research on these two epigenetic regulation factors in the carcinogenesis are reviewed.

Objective To evaluate the early diagnostic value of circulating microRNA-1 (miR-1) on acute myocardial infarction (AMI). Methods A prospective cohort study was conducted. The patients with chest pain admitted to the Second People's Hospital of Wuxi from November 2012 to June 2015 were enrolled. According to AMI diagnostic criteria, the patients were divided into AMI group and non-AMI group, and healthy individuals during the same period were served as heath controls. The venous samples of the onset patients were collected within 3 hours after admission. The plasma miR-1 was determined by real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR), and the levels of plasma cardiac troponin I (cTnI) and MB isoenzyme of creatine kinase (CK-MB) were measured by electrochemiluminescence. The correlation between plasma miR-1 and cTnI as well as CK-MB was performed by Spearman analysis. The early diagnostic performance of plasma miR-1, cTnI, and CK-MB for AMI was estimated by receiver operating characteristic (ROC) curve analysis. Results There were 127 patients in AMI group, and 107 in non-AMI group, including 82 patients with angina pectoris, 2 with pulmonary embolism, 3 with aortic dissection, 2 with acute pericarditis, 3 with myocarditis, 13 with acute heart failure, and 2 with peptic ulcer. Ninety volunteers were served as healthy controls. There was no difference in clinical characteristics including gender and hyperlipidemia between AMI group and non-AMI group. The expressions of plasma miR-1, cTnI and CK-MB were significantly increased in AMI patients as compared with those of the healthy controls [miR-1 (2-ΔΔCt): 4.32±2.60 vs. 1.44±0.75 and 0.98±0.18, cTnI (μg/L): 3.23 (0.63, 10.70) vs. 0.02 (0.00, 0.17) and 0.00 (0.00, 0.00), CK-MB (U/L): 32.40 (14.20, 95.40) vs. 14.40 (11.20, 17.10) and 8.90 (8.28, 9.50), all P < 0.01]. The expression of plasma miR-1 had a significantly positive correlation with cTnI and CK-MB in AMI patients (r1 = 0.395, r2 = 0.490, both P < 0.000). It was demonstrated by ROC curve analysis that the area under ROC curve (AUC) for the diagnostic value of miR-1 on AMI was 0.905 [95% confidence interval (95%CI) = 0.860-0.950, P = 0.000], the sensitivity was 86.6%, and the specificity was 95.4%; the AUC for cTnI was 0.908 (95%CI = 0.870-0.946, P = 0.000), the sensitivity was 81.9%, and the specificity was 95.9%; the AUC for CK-MB was 0.795 (95%CI = 0.736-0.854, P = 0.000), the sensitivity was 63.0%, and the specificity was 92.9%. Conclusions Plasma miR-1 has the capacity in early diagnosis of AMI, superior to CK-MB, and equal to cTnI. It can provide additional diagnostic information beyond cTnI. The diagnostic accuracy for early AMI can be improved with the combination of plasma miR-1 and cTnI.

Objective To evaluate the reporting item quality of randomized controlled trials of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer. Methods The terms including Chinese medicine, Chinese herbal medicine, randomized controlled trials, and non-small cell lung cancer were searched in Chinese and English databases by computer systems to collect relevant literatures. Based on the CONSORT 2010 (consolidated standards of reporting trials 2010), the reporting item quality of the abstracts and main text in eligible papers was evaluated. Results Ninety-five eligible studies were identified from 692 potential eligible articles. None reported all of abstract and main text items in CONSORT 2010. Only 4.12％could be identified as the randomized trial in the title. More than 40％of reports showed the scientific background or rationale in the abstract but not in the main text. Three (3.16％) eligible reports defined the primary or secondary outcome measures. None reported complete information of subjects throughout the clinical trial process. Results A total of 95 eligible papers were collected, of which 0 papers reported complete abstracts and text entries according to the CONSORT. The titles of 4.12％papers were identified as randomized trials. More than 40％of the papers only reported the study purpose or hypothesis in the abstract. 3.16％of the papers reported primary and secondary efficacy index entries, and 0 papers reported complete information of subjects from enrollment to included data analysis sets. Conclusion There is a serious problem of items shortage in the literatures of randomized controlled clinical trials on Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer. The randomized controlled clinical trials of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer should be reported based on the CONSORT to improve the quality of trials.

Objective:To investigate the protein expression level of lysosome-associated transmembrane protein 4β-35 (LAPTM4B-35) and matrix metalloproteinase-9 (MMP-9) in gastric cancer (GC) and to determine the relationship of LAPTM 4B-35 or MMP-9 expres-sion with clinicopathological characteristics and prognosis of patients with GC. Methods:The messenger RNA (mRNA) expression level of LAPTM4B-35 and MMP-9 was detected by real-time quantitative polymerase chain reaction, while the protein expression level of LAPTM 4B-35 and MMP-9 in GC tissues was analyzed by immunohistochemistry in formalin-fixed samples from 152 patients with GC, and data analysis was performed using statistical methods. Results:The mRNA expression level of both LAPTM4B-35 and MMP-9 in HGC-27, SGC 7901, and MGC803 GC cell lines was higher than that in the GES-1 normal gastric mucosa cell line. LAPTM 4B-35 and MMP-9 proteins mainly localized in the cytoplasm of GC cells. The positive LAPTM4B-35 expression ratio in GC tissues was 50.7％, while the MMP-9 positive ratio was 36.8％. LAPTM4B-35 and MMP-9 were positively related to gastric cancer. Lauren's classification and T stage were identified as the relative factors of LAPTM4B-35 expression, while tumor size and N stage were identified as the rela-tive factors of MMP-9 expression in GC tissues. Cox analysis indicated that the degree of differentiation, N stage, LAPTM 4B-35 expres-sion, and MMP-9 expression were independent prognostic indicators for patients with GC. Conclusion:LAPTM4B-35 and MMP-9 play important roles in the aggressiveness of GC, and LAPTM4B-35 and MMP-9 may be promising indicators for the prognosis of patients with GC.

In order to strengthen the supervision of the use of drugs in hospitals，the Sichuan Academy of Medical Sciences· Sichuan Provincial People’s Hospital took the lead in compiling the Principles for the Rational Use of National Key Monitoring Drugs （the Second Batch） with a number of experts from multiple medical units in accordance with the Second Batch of National Key Monitoring Rational Drug Use List （hereinafter referred to as “the List”） issued by the National Health Commission. According to the method of the WHO Guidelines Development Manual， the writing team used the Delphi method to unify expert opinions by reading and summarizing the domestic and foreign literature evidence of related drugs， and applied the evaluation， formulation and evaluation method of recommendation grading （GRADE） to evaluate the quality of evidence formed， focusing on more than 30 drugs in the List about the evaluation of off-label indications of drugs， key points of rational drug use and key points of pharmaceutical monitoring. It aims to promote the scientific standardization and effective management of clinical medication， further improve the quality of medical services， reduce the risk of adverse drug reactions and drug abuse， promote rational drug use， and improve public health.